Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Prognosis of Patients with Diffuse Large B Cell Lymphoma with Central Nervous System Relapse: USC Experience

Lucas Avalon Kaplan, Julian Hardy McLain, Amir Ali, Zaw Win Myint, Anil Tulpule

Blood (2023) 142 (Supplement 1): 6305.

https://doi.org/10.1182/blood-2023-185451

Published: 2023

Journal Articles

Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refractory (R/R) Epstein-Barr Virus (EBV)-Positive B-Cell, T-Cell, and Hodgkin Lymphoma: Interim Safety and Efficacy Results from a Phase 1b/2a Study

Blood (2019) 134 (Supplement_1): 465.

https://doi.org/10.1182/blood-2019-132004

Published: 2019

Journal Articles

The Role of Upfront Hematopoietic Stem Cell Transplantation (HSCT) in Peripheral T-Cell Lymphoma (PTCL) Patients in Complete Remission (CR) with a Special Focus on Nodal PTCL: Report from the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE), a Prospective Multicenter Cohort Study

Blood (2017) 130 (Supplement 1): 342.

https://doi.org/10.1182/blood.V130.Suppl_1.342.342

Published: 2017

Journal Articles

PD-L1 Expression Identifies High Risk Diffuse Large B-Cell Lymphoma and Is Associated with Several Genomic Markers

Imran N Siddiqi, MD PhD, Venkata Thodima, PhD, Julia Friedman, PhD, Adames Violeta, Anil Tulpule, MD, Rita Shaknovich, MD PhD, Jane Houldsworth, PhD

Blood (2016) 128 (22): 153.

https://doi.org/10.1182/blood.V128.22.153.153

Published: 2016

Journal Articles

Racial/Ethnic Disparities in NK/T-Cell Non-Hodgkin Lymphomas in the US: A SEER Analysis

Irene Kang, MD, Dongyun Yang, Mi Hee Park, MD, Ann Mohrbacher, MD, Anil Tulpule, MD, Imran N Siddiqi, MD PhD, Sikander Ailawadhi, MD, Kevin R. Kelly, MD PhD

Blood (2016) 128 (22): 3612.

https://doi.org/10.1182/blood.V128.22.3612.3612

Published: 2016

Journal Articles

Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) with Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results from the Pyramid Trial (NCT00931918)

Blood (2015) 126 (23): 811.

https://doi.org/10.1182/blood.V126.23.811.811

Published: 2015

Journal Articles

Genomic Complexity in Diffuse Large B-Cell Lymphoma Is Associated with p53 Expression and Inferior Survival

Charles Ma, PhD, Imran N Siddiqi, MD PhD, Yi Xie, MD PhD, Anil Tulpule, MD, Jane Houldsworth, PhD

Blood (2014) 124 (21): 3023.

https://doi.org/10.1182/blood.V124.21.3023.3023

Published: 2014

Journal Articles

Patient Characteristics and Initial Treatment Patterns in the United States for the Most Common Subtypes of Peripheral T-Cell Lymphoma (PTCL)

Blood (2014) 124 (21): 4434.

https://doi.org/10.1182/blood.V124.21.4434.4434

Published: 2014

Journal Articles

Rituximab Plus CHOP Given Every 15 Days with GM-CSF (sargramostim) In Patients Withnewly Diagnosed Diffuse Large B-Cell Lymphoma

Anil Tulpule, MD, Nancy Berman, Nazish Ahmed, William Boswell, Mary El-Masry, Preet Chaudhary, MD, PhD

Blood (2010) 116 (21): 4886.

https://doi.org/10.1182/blood.V116.21.4886.4886

Published: 2010

Journal Articles

Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma

Ren Liu, Ming Gong, Xiuqing Li, Yue Zhou, Wenming Gao, Anil Tulpule, Preet M. Chaudhary, Jae Jung, Parkash S. Gill

Blood (2010) 116 (2): 297–305.

https://doi.org/10.1182/blood-2009-12-257154

Published: 2010

Includes: Supplemental data

Journal Articles

KSHV-induced notch components render endothelial and mural cell characteristics and cell survival

Ren Liu, Xiuqing Li, Anil Tulpule, Yue Zhou, Jeffrey S. Scehnet, Shaobing Zhang, Jong-Soo Lee, Preet M. Chaudhary, Jae Jung, Parkash S. Gill

Blood (2010) 115 (4): 887–895.

https://doi.org/10.1182/blood-2009-08-236745

Published: 2010

Includes: Supplemental data

Journal Articles

Phase 1/2a Study of ABT-263 in Relapsed or Refractory Lymphoid Malignancies.

Wyndham H Wilson, MD, PhD, Owen A O'Connor, MD, PhD, Myron S Czuczman, Ann LaCasce, MD, John Gerecitano, MD, PhD, John P. Leonard, MD, Anil Tulpule, MD, Hao Xiong, Ph.D., Yi-Lin Chiu, Todd Busman, Sari Enschede, Andrew Krivoshik, Rod Humerickhouse

Blood (2009) 114 (22): 1711.

https://doi.org/10.1182/blood.V114.22.1711.1711

Published: 2009

Journal Articles

Phase 1 Study of ABT-263, a Bcl-2 Family Inhibitor, in Relapsed or Refractory Lymphoid Malignancies.

Wyndham H Wilson, MD, PhD, O. O’Connor, M.D., Myron S. Czuczman, MD, Ann LaCasce, MD, J. Gerecitano, M.D., Ph.D., John P. Leonard, MD, Anil Tulpule, MD, Hao Xiong, Ph.D., Yi-Lin Chiu, Ph.D., Todd Busman, Ph.D., Raymond A. Knight, MBA, Sari Enschede, M.D., Andrew Krivoshik, M.D., Ph.D., Rod Humerickhouse, M.D., Ph.D

Blood (2008) 112 (11): 2108.

https://doi.org/10.1182/blood.V112.11.2108.2108

Published: 2008

Journal Articles

A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Refractory or Relapsed Lymphoid Malignancies.

Wyndham H. Wilson, Anil Tulpule, Alexandra M. Levine, Kieron Dunleavy, Andrew P. Krivoshik, Anne E. Hagey, Margaret Shovlin, Melanie A. Gloria, Renee Greco, Hao Xiong, Yi-Lin Chiu, Steven W. Elmore, Owen A. O’Connor

Blood (2007) 110 (11): 1371.

https://doi.org/10.1182/blood.V110.11.1371.1371

Published: 2007

Journal Articles

Phase II Results of Bendamustine in Combination with Rituximab in Relapsed Indolent and Mantle-Cell Non-Hodgkin’s Lymphoma.

Richard H. Van der Jagt, MD, Philip Cohen, MD, Bruce D. Cheson, MD, Anil Tulpule, MD, Jordan A. Herst, MD,FRCP, Bernard Lemieux, MD, Lee S. Schwartzberg, MD, Katherine Sue Robinson, MD, Jennifer W. Oliver, MD, Michael E. Williams, MD

Blood (2006) 108 (11): 2710.

https://doi.org/10.1182/blood.V108.11.2710.2710

Published: 2006

Journal Articles

Phase I Study of Noscapine for Patients with Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy.

Anil Tulpule, MD, Alexandra M. Levine, MD, Nancy E. Berman, RN, BSN, Lynne Smith, PhD, Alan Auerbach, Dan Douer, MD

Blood (2005) 106 (11): 3341.

https://doi.org/10.1182/blood.V106.11.3341.3341

Published: 2005

Journal Articles

Bendamustine HCl (TREANDA TM ) Treatment in Combination with Rituximab Results in Objective Responses in Patients with Refractory/Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin’s Lymphoma: Results from Phase II Multicenter Study (SDX-105-02).

Katherine Sue Robinson, MD, Michael E. Williams, MD, Philip Cohen, MD, Anil Tulpule, MD, Richard H. van der Jagt, MD, Jordan A. Herst, MD, Robin M. Joyce, MD, Alberto Bessudo, MD, Bernard Lemieux, MD, Lee S. Schwartzberg, MD, Jennifer Oliver, MD, Ely Benaim, MD

Blood (2005) 106 (11): 923.

https://doi.org/10.1182/blood.V106.11.923.923

Published: 2005

Journal Articles

Results of a Pilot Trial of Fludarabine, Mitoxantrone and Rituxan in Mantle Cell Lymphoma.

Alexandra M. Levine, MD, Anil Tulpule, MD, Lynne Smith, PhD, Byron M. Espina, AB, Ann F. Mohrbacher, MD, Donald I. Feinstein, MD

Blood (2005) 106 (11): 945.

https://doi.org/10.1182/blood.V106.11.945.945

Published: 2005

Journal Articles

Ephrin B2 expression in Kaposi sarcoma is induced by human herpesvirus type 8: phenotype switch from venous to arterial endothelium

Rizwan Masood, Guangbin Xia, D. Lynne Smith, Piergips Scalia, Jonathan G. Still, Anil Tulpule, Parkash S. Gill

Blood (2005) 105 (3): 1310–1318.

https://doi.org/10.1182/blood-2004-03-0933

Published: 2005

Journal Articles

Treatment of Anemia with Aranesp® (Darbepoetin-alfa) Given Once Every Two Weeks in HIV Seropositive Patients.

Anil Tulpule, M.D., Dharshika Dharmapala, Pamela Burian, PA-C, Byron M. Espina, Gerald Jayne, Shelly George, M.D., Alexandra M. Levine, M.D.

Blood (2004) 104 (11): 3108.

https://doi.org/10.1182/blood.V104.11.3108.3108

Published: 2004

NARROW

Prognosis of Patients with Diffuse Large B Cell Lymphoma with Central Nervous System Relapse: USC Experience

PD-L1 Expression Identifies High Risk Diffuse Large B-Cell Lymphoma and Is Associated with Several Genomic Markers

Racial/Ethnic Disparities in NK/T-Cell Non-Hodgkin Lymphomas in the US: A SEER Analysis

Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) with Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results from the Pyramid Trial (NCT00931918)

Genomic Complexity in Diffuse Large B-Cell Lymphoma Is Associated with p53 Expression and Inferior Survival

Patient Characteristics and Initial Treatment Patterns in the United States for the Most Common Subtypes of Peripheral T-Cell Lymphoma (PTCL)

Rituximab Plus CHOP Given Every 15 Days with GM-CSF (sargramostim) In Patients Withnewly Diagnosed Diffuse Large B-Cell Lymphoma

Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma

KSHV-induced notch components render endothelial and mural cell characteristics and cell survival

Phase 1/2a Study of ABT-263 in Relapsed or Refractory Lymphoid Malignancies.

Phase 1 Study of ABT-263, a Bcl-2 Family Inhibitor, in Relapsed or Refractory Lymphoid Malignancies.

A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Refractory or Relapsed Lymphoid Malignancies.

Phase II Results of Bendamustine in Combination with Rituximab in Relapsed Indolent and Mantle-Cell Non-Hodgkin’s Lymphoma.

Phase I Study of Noscapine for Patients with Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy.

Bendamustine HCl (TREANDA TM ) Treatment in Combination with Rituximab Results in Objective Responses in Patients with Refractory/Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin’s Lymphoma: Results from Phase II Multicenter Study (SDX-105-02).

Results of a Pilot Trial of Fludarabine, Mitoxantrone and Rituxan in Mantle Cell Lymphoma.

Ephrin B2 expression in Kaposi sarcoma is induced by human herpesvirus type 8: phenotype switch from venous to arterial endothelium

Treatment of Anemia with Aranesp® (Darbepoetin-alfa) Given Once Every Two Weeks in HIV Seropositive Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only